Scholarlink

Purpose <p>Immunotherapy is emerging as a promising approach for cervical cancer treatment, with new targets and drugs continuously being developed. In response to the wide range of immunotherapies currently available, this article aims to review and sort the immunotherapy for cervical cancer and the advancements in assessing effectiveness and prognosis.</p> Results <p>The result shows that immune checkpoint inhibitors are highly effective in various immunotherapies for cervical cancer. The most commonly used immunotherapies for advanced cervical cancer are programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors. Other options include tumor cell vaccines and genetically engineered T-cells. It is important to note that immunotherapy in combination with other treatments has been shown to be more effective than using immunotherapy alone. Moreover, when considering treatment efficacy, it may be helpful to focus on biomarkers such as Circulating Tumor Cells (CTCs), microRNAs, Long Non-coding RNAs, Circular RNAs, Tumor Mutational Burden (TMB), and tumor infiltrating lymphocytes (TILs).</p> Conclusion <p>This review catches the latest progress in immunotherapy for cervical cancer and in assessing effectiveness and prognosis. Immunotherapy, particularly immune checkpoint inhibitors, is gaining ground in cervical cancer treatment. Relevant studies on biological indicators for the assessment of the efficacy of immunotherapy are also under way.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of immunotherapy in cervical cancer: a review of advances in immune-related therapy for cervical cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月18日

查看全文
  • Jing Liu,
  • Yaxin Kang,
  • Li Li,
  • Lele Zang,
  • Lan Luo,
  • Fei Zhu,
  • Mingxuan Zhu,
  • Huiqi Zhang,
  • Qin Xu

摘要

Purpose

Immunotherapy is emerging as a promising approach for cervical cancer treatment, with new targets and drugs continuously being developed. In response to the wide range of immunotherapies currently available, this article aims to review and sort the immunotherapy for cervical cancer and the advancements in assessing effectiveness and prognosis.

Results

The result shows that immune checkpoint inhibitors are highly effective in various immunotherapies for cervical cancer. The most commonly used immunotherapies for advanced cervical cancer are programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors. Other options include tumor cell vaccines and genetically engineered T-cells. It is important to note that immunotherapy in combination with other treatments has been shown to be more effective than using immunotherapy alone. Moreover, when considering treatment efficacy, it may be helpful to focus on biomarkers such as Circulating Tumor Cells (CTCs), microRNAs, Long Non-coding RNAs, Circular RNAs, Tumor Mutational Burden (TMB), and tumor infiltrating lymphocytes (TILs).

Conclusion

This review catches the latest progress in immunotherapy for cervical cancer and in assessing effectiveness and prognosis. Immunotherapy, particularly immune checkpoint inhibitors, is gaining ground in cervical cancer treatment. Relevant studies on biological indicators for the assessment of the efficacy of immunotherapy are also under way.